Investigating the Effect of Coated Lipid Nano Particles of Spironolactone with Chitosan on Their Properties

Background and Solid lipid nanoparticles are in the colloid carriers. The benefits of these drug carriers are the controlled release of the drug and the protection of the drug being loaded. Spironolactone is an aldosterone antagonist and androgen receptor. Its oral bioavailability is low due to the low solubility of this drug and its slow release. Reducing particle size by increasing the level of the drug leads to increased release, higher oral bioavailability, higher particle size in contact with the dissolution medium, and increasing the dissolvability of the drug saturation.
Solvent emulsification/evaporation was used to prepare spironolactone nanoparticles. For this purpose, the lipid and drug were dissolved in an appropriate organic solvent and added to the aqueous phase containing surfactant during mixing by homogenizer. After coated with chitosan, the chitosan was dissolved in dilute acid and was added to the suspension on the stirrer drop by drop.
By maintaining the amount of lipid in the formulation and increasing the amount of surfactant, the particle size decreased significantly. In general, the coating of spironolactone nanoparticles with chitosan increased the particle size and their dispersion, and the zeta potential changed from a negative value to a positive value.
Spironolactone coated with chitosan was found to have a slower release than solid lipid nanoparticles and nanosuspension.